...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics.
【24h】

Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics.

机译：丙型肝炎病毒感染中的趋化因子：发病机理，预后和治疗方法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hepatitis C virus infection and its associated liver inflammatory disease is a major global health problem affecting over 170 million people worldwide. Following viral infection, multiple pro-inflammatory mediators contribute to recruitment of immune cells to the liver and to the generation of an anti-viral immune response. However, when this vigorous immune response fails to eliminate the virus, chronic infection is established. This in turn, results in an ongoing process of inflammation, regeneration and fibrosis that in many cases leads to the development of cirrhosis and of hepatocellular carcinoma. Multiple recent publications mark chemokines and their receptors as key players in leukocyte recirculation through the inflamed liver. Furthermore, chemokines may also be involved in liver regeneration, fibrosis, and in malignant transformation, which is induced by the persistence of inflammation. Accumulating data indicates that distinct chemokines and chemokine receptors may be associated with different stages of the chronic hepatitis C virus infection-associated liver disease. Multiple small molecules and peptide antagonizing chemokines and their receptors are in advanced phase 3 and phase 2 clinical trials. In the near future, such drugs are expected to enter clinical use raising the question whether they may be applicable for the treatment of chronic viral infection-associated liver disease. In this review, recent advances in understanding the role of chemokines and their receptors in the pathogenesis of chronic viral infection-associated liver disease are presented. Furthermore, the clinical implications of these novel findings, which mark chemokines as prognostic markers and therapeutic targets for immune-modulation during chronic liver viral infection, are documented.
机译：丙型肝炎病毒感染及其相关的肝炎性疾病是一个严重的全球性健康问题，影响了全世界超过一亿七千万人。病毒感染后，多种促炎性介质有助于免疫细胞向肝脏的募集和抗病毒免疫反应的产生。但是，当这种剧烈的免疫反应未能消除病毒时，便建立了慢性感染。这进而导致炎症，再生和纤维化的持续过程，在许多情况下导致肝硬化和肝细胞癌的发展。最近的许多出版物将趋化因子及其受体标记为通过发炎的肝白细胞再循环的关键因素。此外，趋化因子也可能参与肝脏的再生，纤维化和恶性转化，这是由炎症的持续存在引起的。越来越多的数据表明，不同的趋化因子和趋化因子受体可能与慢性丙型肝炎病毒感染相关的肝病的不同阶段有关。多种小分子和肽拮抗趋化因子及其受体正在进行晚期3期和2期临床试验。预计在不久的将来，此类药物将进入临床，这引发了人们疑问，这些药物是否可用于治疗与慢性病毒感染相关的肝病。在这篇综述中，提出了在理解趋化因子及其受体在慢性病毒感染相关肝病发病机理中的作用的最新进展。此外，已记录了这些新发现的临床意义，这些新发现将趋化因子标记为慢性肝病毒感染期间免疫调节的预后标志物和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号